Lot-document scope confirmed before quotation · Research use only
  • Specification Review
  • Lot Documents on Request
  • Business Support · Xi’an
  • Destination Eligibility Confirmed
西安诺和达生物科技有限公司

Research & insights

MK-677 / Ibutamoren: Clinical Status, Heart-Failure Signal and Material Questions

By NHD Technical TeamPublished
Biomedical illustration of receptor biology and a cardiac safety boundary
Article-specific editorial image.

MK-677, MK-0677 and ibutamoren are names found across the same development history. The existence of human trials does not mean the compound is an approved drug, nor does it erase trials that failed to show functional benefit or raised safety concerns.

What the record shows

  • Ibutamoren is not an FDA-approved active ingredient.
  • A 123-patient hip-fracture trial was stopped early after a congestive-heart-failure signal.
  • Identity and assay must distinguish ibutamoren free form from ibutamoren mesylate.
Scientist reviewing pulsatile growth-hormone and IGF-1 research data
Original editorial illustration used to identify the research theme. It does not depict a catalog lot, approved drug, assay result or clinical use.

The identity and evidence boundary

A certificate should state the exact molecular form, not use the parent name and mesylate interchangeably. Molecular mass, assay calculation and content per container depend on that choice.

Synonyms in literatureMK-677, MK-0677, ibutamoren
Salt/form issueIbutamoren vs ibutamoren mesylate
Safety contextGlucose/insulin effects, edema and CHF signal

What belongs in the material record

Marketing summaries frequently select the increase in IGF-1 or fat-free mass and omit the negative functional outcomes. A defensible page keeps the outcome hierarchy intact and cites the stopped hip-fracture trial as well as the longer healthy-older-adult study.

Editorial rule

Use the exact intervention name, model, population and endpoint from the cited record. Do not convert an association, mechanism, animal result, approved finished-drug record or analytical test into a claim about an unrelated catalog lot.

Sources & editorial method

The editorial workflow starts with linked peer-reviewed papers, trial registries or regulatory records; extracts the population or model, endpoints, numerical results and limitations; and separates the studied intervention from catalog material. AI-assisted drafting was used to structure the first version. Claims, figures, evidence labels and limitations were checked against the linked records in the site editorial workflow. This is not independent peer review.

3 linked records are listed in the references below. Read the editorial and AI-assistance policy.

How to interpret this article

Source-checked on 2026-08-28. Null findings and study limitations are retained. This is not independent peer review, medical advice, a customer case, or validation of a catalog lot.

Research-use boundary: Catalog materials discussed on this website are for laboratory research, development and manufacturing use only, not for human or veterinary use. This content is not medical advice and does not provide administration instructions.

Primary records and authoritative sources

  1. MK-677 in healthy older adultsNass R, et al. Annals of Internal Medicine. 2008. PMID 18981485.
  2. MK-0677 phase IIb hip-fracture studyAdunsky A, et al. Archives of Gerontology and Geriatrics. 2011. PMID 21067829.
  3. FDA Pharmacy Compounding Advisory Committee meeting materialsFDA assessment materials for ibutamoren and ipamorelin.
Research pathways

Continue with structured records

Move from this editorial analysis to the product identity, filtered evidence and controlled terminology behind it.

Editorial source check: NHD evidence editorial workflow · 2026-08-28